Business Wire

The Digital Cooperation Organization Hosted Its First Collaborative Roundtable With Social Media, Technology Companies, and Digital Platforms to Combat the Spread of Online Misinformation

Share

The Digital Cooperation Organization (DCO), a global multilateral organization committed to enabling digital prosperity for all by accelerating the sustainable and inclusive growth of the digital economy, hosted a strategic roundtable discussion with major technology companies, and social media and digital platform representatives to address the societal impact of the spread of online misinformation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240828374432/en/

Representatives from social media, technology companies, and digital platforms at the DCO HQ (Photo AETOSWire)

Building on the series of global roundtables conducted in 2023 as part of the “combating online misinformation” Digital Space Accelerators, this roundtable continuous the DCO’s ongoing efforts to combat online misinformation. Representatives from Google, LinkedIn, Meta and TikTok participated as key stakeholders to discuss this crucial issue affecting the digital world.

The roundtable, held at the DCO headquarters in Riyadh, Saudi Arabia, aimed to identify challenges and propose innovative solutions to foster trust and safeguard the digital economy. The participation of representatives from social media and digital platforms underscored the importance of the roundtable, providing a crucial platform for stakeholders to exchange perspectives and explore collaborative actions to combat online misinformation.

The discussions aimed to create an ongoing dialogue on the gravity of online misinformation as both a societal problem and a challenge to the digital economy. It also provided a platform for stakeholders to bridge their perspectives and work together to combat online misinformation, thereby ensuring a trustworthy digital information ecosystem.

"The exchange of ideas and insights from leading platforms has been invaluable. The key takeaway from the discussion was the importance of cooperation through a multistakeholder approach to combat online misinformation, which aligns with the DCO’s mission. We are confident that the outcomes of this roundtable will pave the way for a more informed and resilient digital society, and we look forward to our next collaborative roundtable to enable digital prosperity for all", said Alaa Abdulaal, Chief of the Digital Economy Foresight department at the Digital Cooperation Organization.

Sarah Al-Husseini, Head of Government Affairs & Public Policy, KSA at Google, said: People come to Google because they trust they will be able to find high quality information, which is why we take our commitment to combating misinformation through our products and our content policies very seriously. We work hard to retain that trust - designing our systems for quality and ensuring users are given access to a range of information from different voices and the tools to know what they can trust. We do not do it alone; in addition to continuously adapting our policies and technologies to prevent abuse, we openly share our technology and collaborate with experts to drive the industry forward and create a safer internet for everyone.

Ranim Alamin, Strategic Government Partnerships Head, KSA at LinkedIn, said: Taking part in the DCO's strategic roundtable offered us a valuable opportunity to discuss one of the more pressing issues in the digital world: Misinformation. The conversations we had with representatives from various leading platforms underscored the importance of a united approach to foster trust. We are committed to working together to build a more trusted and resilient digital information ecosystem.”

Tom Bonsundy-O'Bryan, Misinformation Policy, EMEA Lead at Meta, said: We were glad to attend this roundtable organized by the DCO and remain deeply committed to tackling misinformation - balancing our values of expression, safety, authenticity and privacy.”

Hatem Samman, Executive Director of Government Relations & Public Policy, KSA at TikTok, said: “At TikTok, we are committed to fostering a secure and trustworthy digital environment for the community. This roundtable provided an essential platform for discussing innovative strategies and collaborative actions to combat misinformation. By working together, we can create a safe, authentic space where people can discover content that is original and engage with people who are authentic.”

The Digital Cooperation Organization remains committed to fostering a collaborative approach to combating misinformation and ensuring the growth of the digital economy. The DCO looks forward to continuing this impactful work with its partners in the social media and digital platform space.

*Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20240828374432/en/

Contacts

Ahmed Bayouni
Media@dco.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina17.9.2025 15:30:00 EEST | Press release

Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-derived organoids (PDXO), and patient-derived organoids (PDO), to meet the evolving needs of pharmaceutical and biotechnology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917864004/en/ Crown Bioscience celebrate the official ribbon-cutting ceremony for the company’s new Kannapolis, North Carolina facility, marking an expansion of US oncology model development and preclinical CRO services. The new facility strengthens Crown Bioscience’s US-based capabil

SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 15:00:00 EEST | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth

Merck to Present New Data Highlighting Durable Effects of MAVENCLAD ® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 15:00:00 EEST | Press release

Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in Barcelona. “As the only high-efficacy short-course oral treatment, MAVENCLAD has demonstrated sustained benefits across a variety of outcomes—extending beyond relapses and MRI—without requiring continuous immunosuppression,” said Alex Kulla, Senior Vice President & Global Head of the Neurology & Immunology Medical Unit for the Healthcare business of Merck. “With over two decades of clinical experience an

Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 15:00:00 EEST | Press release

Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 1b/2a study with lead drug candidate RLS-1496 in patients with actinic keratosis. RLS-1496 is a first-in-class disease-modifying selective glutathione peroxidase 4 (GPX4) modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process. The study is expected to begin in Q4 2025. The first EMA-cleared RLS-1496 clinical trial began in May 2025 for plaque psoriasis, atopic dermatitis, and skin aging (photoaged skin); study results are expected in Q4 2025. Actinic keratosis is a rough, scaly patch caused by sun exposure that appears on sun-exposed areas of the skin, such as

New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 15:00:00 EEST | Press release

Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers to higher-acuity care units, achieved through earlier detection and intervention to prevent patient deterioration.2-5 Now, in this new retrospective analysis – involving 3-1/2 years of data and almost

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye